Compare APOG & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APOG | ABUS |
|---|---|---|
| Founded | 1949 | 2005 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 835.9M | 888.5M |
| IPO Year | 1994 | 2008 |
| Metric | APOG | ABUS |
|---|---|---|
| Price | $40.83 | $4.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $47.00 | $5.00 |
| AVG Volume (30 Days) | 203.6K | ★ 1.7M |
| Earning Date | 04-09-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.64% | N/A |
| EPS Growth | N/A | ★ 13.64 |
| EPS | ★ 1.74 | N/A |
| Revenue | ★ $1,360,994,000.00 | $6,171,000.00 |
| Revenue This Year | $4.12 | $125.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.52 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.75 | $2.71 |
| 52 Week High | $49.64 | $5.10 |
| Indicator | APOG | ABUS |
|---|---|---|
| Relative Strength Index (RSI) | 58.25 | 48.15 |
| Support Level | $40.58 | $3.93 |
| Resistance Level | $43.36 | $4.34 |
| Average True Range (ATR) | 1.25 | 0.34 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 61.93 | 57.27 |
Apogee Enterprises Inc is a provider of architectural products and services for enclosing buildings, and high-performance glass and acrylic products used in applications for preservation, protection, and enhanced viewing. The company's operating segment consists of the Architectural Metals Segment, Architectural Services Segment, Architectural Glass Segment, and Performance Surfaces Segment. The company generates the majority of its revenue from the Architectural Metals Segment, which designs, engineers, fabricates, and finishes aluminum window, curtainwall, storefront, and entrance systems used principally in non-residential construction. The company generates revenue geographically from the United States, Canada, and Brazil, with the majority coming from the United States.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.